Corcoran et al v. CVS Health Corporation

Northern District of California, cand-4:2015-cv-03504

Proposed Order

Interested in this case?

Current View

Full Text

1 UNITED STATES DISTRICT COURT 2 NORTHERN DISTRICT OF CALIFORNIA 3 OAKLAND DIVISION 4 CHRISTOPHER CORCORAN, et al., No. 15-CV-03504-YGR 5 Plaintiffs, 6 [PROPOSED] ORDER GRANTING v. DEFENDANT'S ADMINISTRATIVE 7 MOTION TO FILE UNDER SEAL RE: CVS PHARMACY, INC., CVS'S MOTIONS IN LIMINE AND 8 OMNIBUS OPPOSITION TO Defendant. PLAINTIFFS' MOTIONS IN LIMINE 9 10 11 On May 5, 2020, CVS Pharmacy, Inc. ("CVS") filed an Administrative Motion to File 12 Under Seal Materials Designated Confidential Re: CVS's Motions in Limine and Omnibus 13 Opposition to Plaintiffs' Motions in Limine ("Motion to Seal") in the above-captioned action 14 pursuant to Local Rules 7-11 and 79-5. 15 The Court, having considered CVS's Motion to Seal, all papers and evidence submitted 16 in support, the pertinent pleadings, and the applicable law, and finding compelling reasons and 17 good cause therefore, hereby GRANTS the Motion to Seal. It is ORDERED that the following 18 materials are to be filed under seal pursuant to Civil Local Rule 79-5(b) and (e): 19 20 Document or Portion of Document Evidence Offered in Support of Order 21 Sought to Be Sealed Sealing 22 Exhibit 11 (Declaration of Bretta Moffatt Declaration ¶¶ 4, 4.a 23 Grinsteinner (April 1, 2019)) [sealed in its 24 entirety] 25 Exhibit 12 (Declaration of Justin Kaiser Moffatt Declaration ¶¶ 4, 4.b 26 (March 6, 2019)) [sealed in its entirety] 27 Exhibit 13 (Declaration of Darren Gettings, Moffatt Declaration ¶¶ 4, 4.c 28 [PROPOSED] ORDER GRANTING -1- ADMINISTRATIVE MOTION TO FILE UNDER SEAL, NO. 15-CV-03504-YGR 1 R.Ph. (March 8, 2019)) [sealed in its 2 entirety] 3 Exhibit 17 (excerpts from OptumRx, Inc. Moffatt Declaration ¶¶ 5, 5.a 4 Pharmacy Network Agreement (Jan. 29, 5 2015)) [sealed in its entirety except for § 6 1.41] 7 Exhibit 18 (excerpts from Prescription Moffatt Declaration ¶¶ 5, 5.b 8 Solutions Prescription Drug Services 9 Agreement (June 1, 1999) [sealed in its 10 entirety except for page 12, paragraph 11 relating to "Usual and Customary"] 12 Exhibit 19 (excerpts from PCS Health Moffatt Declaration ¶¶ 5, 5.c 13 Systems, Inc. Provider Agreement (Mar. 14 31, 1997) [sealed in its entirety except for 15 page 20, paragraph relating to "Usual and 16 Customary Price"] 17 Exhibit 20 (excerpts from Express Scripts, Moffatt Declaration ¶¶ 5, 5.d 18 Inc. Pharmacy Provider Agreement (Jan. 19 18, 2008)) [sealed in its entirety except for 20 §§ 1.17 and 2.4(a)] 21 Exhibit 21 (Medco Health Solutions, Inc. Moffatt Declaration ¶¶ 5, 5.e 22 Retail Pharmacy Agreement (Jan. 1, 2005)) 23 [sealed in its entirety except for § 2.6, ¶ 1] 24 Exhibit 22 (MedImpact Pharmacy Network Moffatt Declaration ¶¶ 5, 5.f 25 Agreement (Feb. 1, 2008)) [sealed in its 26 entirety except for page 20, paragraphs 27 relating to "Usual and Customary or 28 [PROPOSED] ORDER GRANTING -2- ADMINISTRATIVE MOTION TO FILE UNDER SEAL, NO. 15-CV-03504-YGR 1 U&C") 2 Exhibit 24 (Expert Report of Professor Joel Moffatt Declaration ¶¶ 6, 6.a 3 W. Hay, Ph.D.) at page 8, ¶ 33; page 9, ¶¶ 4 34–35; page 10, ¶¶ 35, 39; page 11, ¶ 39; 5 page 12, ¶ 42, fn. 16; page 13, fn. 16; page 6 17, ¶¶ 63–64; page 18, ¶¶ 64–67. 7 Exhibit 25 (Rebuttal Report of Professor Moffatt Declaration ¶¶ 6, 6.b 8 Joel W. Hay, Ph.D.) at page 14 ¶ 40, fn. 24; 9 page 15 ¶¶ 42–44. 10 Exhibit 26 (Expert Report of Brett E. Moffatt Declaration ¶¶ 6, 6.c 11 Barlag (Dec. 9, 2016)) at page 8 ¶ 22; page 12 11 ¶ 27.c, Fig. 1, fn. 8; page 12 ¶ 29; page 13 13 ¶¶ 33–37; page 15 Fig. 4; page 17 Fig. 14 7; page 18 Fig. 9; page 19 ¶ 51; page 24 15 Fig. 12, ¶ 65; page 25 ¶¶ 66-68; page 26 ¶¶ 16 68–71, Fig. 13, fn. 60; page 29 Fig. 16; 17 page 38 ¶¶ 102–103; page 39 ¶ 105, fns. 18 92–93; page 40 ¶ 106; page 42 ¶¶ 115 (b), 19 116; page 43 ¶¶ 116–118, Fig. 20; page 44 20 Fig. 21; page 47 ¶ 124, fn. 108; Appendix 21 A; Appendix D; and Appendix E 22 Exhibit 27 (Declaration of Professor Joel Moffatt Declaration ¶¶ 6, 6.d 23 W. Hay, Ph.D.) at page 8 ¶¶ 32–33; page 9 24 ¶¶ 33–34; page 10 ¶ 38; page 12 ¶ 42; page 25 14 ¶ 52. 26 Exhibit 29 (Rebuttal Report of Brett E. Moffatt Declaration ¶¶ 6, 6.e 27 Barlag (Jan. 27, 2017)) at page 3 fn. 3; 28 [PROPOSED] ORDER GRANTING -3- ADMINISTRATIVE MOTION TO FILE UNDER SEAL, NO. 15-CV-03504-YGR 1 page 12 ¶ 26, fn. 28; page 13 ¶ 27; page 14 2 ¶¶ 28–29, Fig. 7; page 15 ¶¶ 29–31, page 3 16 ¶ 32, Fig. 8; page 17 ¶¶ 36.a, 36.b, fn. 4 39; page 19 ¶ 38; and Appendix B 5 Exhibit 31 (Deposition of Carl Washington Moffatt Declaration ¶¶ 7, 7.a 6 (Aug. 30, 2016)) at page 210, lines 10–12; 7 page 212, lines 17–23; page 213, lines 9– 8 25; page 214, line 1; page 217, lines 1–13; 9 page 263, lines 2–4 and 21–25; page 264, 10 lines 1–4; page 268, lines 22–25; page 269, 11 lines 1–6 12 Exhibit 32 (Deposition of Tyler Clark (Oct. Moffatt Declaration ¶¶ 7, 7.b 13 26, 2016)) at page 86, lines 10–12; page 14 89, lines 6–7; page 176, lines 18–25; page 15 177, lines 1–10 16 Exhibit 33 (Deposition of Darlene McAfee Moffatt Declaration ¶¶ 7, 7.c 17 (Sept. 25, 2019)) at page 57, lines 8–19; 18 page 88, lines 5–25; page 89, lines 1–25 19 Exhibit 34 (Deposition of Deborah Barrett Moffatt Declaration ¶¶ 7, 7.d 20 (Sept. 16, 2016)) at page 39, lines 24–25; 21 page 40, lines 1–2 and 21–25; page 41, 22 lines 1–15; page 43, lines 2–9; page 58, 23 lines 10–23; page 60, lines 2–5 24 Exhibit 35 (Deposition of Robert Jenks Moffatt Declaration ¶¶ 7, 7.e 25 (July 28, 2016)) at page 28, lines 23–24; 26 page 29, lines 9–14; page 83, lines 17–19; 27 page 115, lines 6–9 28 [PROPOSED] ORDER GRANTING -4- ADMINISTRATIVE MOTION TO FILE UNDER SEAL, NO. 15-CV-03504-YGR 1 CVS's Motion in Limine #3 at page 2:16– Moffatt Declaration ¶¶ 8, 8.a 2 23, fns. 5–6 and page 3:1, fn.7 3 CVS's Motion in Limine #5 at page 2:21– Moffatt Declaration ¶¶ 8, 8.b 4 22 5 6 Dated: ______________ ______________________ 7 Hon. Yvonne Gonzalez Rogers United States District Court 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 [PROPOSED] ORDER GRANTING -5- ADMINISTRATIVE MOTION TO FILE UNDER SEAL, NO. 15-CV-03504-YGR